7 completed, 3 terminated, 2 withdrawn, 1 active not recruiting. 6 Phase 2, 4 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow Lung Biotechnology PBC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease UKidney - Kidney Failure, Chronic | Phase 1 | Withdrawn | University of Alabama at Birmingham | 2024-01-31 | 2024-02-01 | |
| A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension Parenteral Treprostinil, Oral Treprostinil - Pulmonary Arterial Hypertension | Phase 4 | Active not recruiting | United Therapeutics | 52 | 2022-10-20 | 2025-12-09 |
| Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH Treprostinil, Non-Treprostinil PAH Medications - Pulmonary Arterial Hypertension | Completed | United Therapeutics | 43 | 2019-04-01 | 2021-03-16 | |
| Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) Inhaled treprostinil solution - Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | United Therapeutics | 41 | 2018-12-21 | 2026-05-27 |
| A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension Esuberaprost, Placebo - Pulmonary Arterial Hypertension | Phase 3 | Terminated | Lung Biotechnology PBC | 112 | 2018-12-10 | 2020-09-07 |
| Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH) BPS-314d-MR - Pulmonary Arterial Hypertension | Phase 2 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 1 | 2013-11-01 | 2020-10-20 |
| Beraprost-314d Added-on to Tyvaso® (BEAT) Beraprost Sodium 314d Modified Release Tablets, Placebo - Pulmonary Arterial Hypertension | Phase 3 | Completed | Lung Biotechnology PBC | 273 | 2013-05-31 | 2020-08-03 |
| A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor Beraprost Sodium 314d Modified Release Tablets, Placebo - Pulmonary Arterial Hypertension | Phase 3 | Withdrawn | Lung Biotechnology PBC | 2011-11-01 | 2012-05-14 | |
| Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) Beraprost Sodium Modified Release - Pulmonary Arterial Hypertension | Phase 2 | Completed | Lung Biotechnology PBC | 36 | 2010-02-01 | 2020-09-30 |
| Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients Beraprost Sodium Modified Release - Pulmonary Arterial Hypertension | Phase 2 | Completed | Lung Biotechnology PBC | 31 | 2009-11-30 | 2019-09-16 |
| An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients Beraprost Sodium Modified Release - Pulmonary Arterial Hypertension | Phase 2 | Completed | Lung Biotechnology PBC | 18 | 2009-02-28 | 2019-12-26 |
| A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients Beraprost sodium modified release - Pulmonary Arterial Hypertension | Phase 2 | Completed | Lung Biotechnology PBC | 19 | 2009-01-31 | 2020-06-09 |
| Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis Treprostinil sodium for inhalation - Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension | Phase 2 | Terminated | Lung Biotechnology PBC | 1 | 2008-06-01 | 2018-05-11 |
Pulmonary Arterial Hypertension (10) · Hypertension, Pulmonary (4) · Hypertension (3) · Lung Diseases (3) · Vascular Diseases (2) · Cardiovascular Diseases (1) · Familial Primary Pulmonary Hypertension (1) · Idiopathic Pulmonary Fibrosis (1) · Kidney Failure, Chronic (1) · Motor Activity (1) · Pulmonary Disease, Chronic Obstructive (1) · Pulmonary Fibrosis (1) · Respiratory Tract Diseases (1)
beraprost (4) · treprostinil (3) · Inhalation (1) · Transplantation, Heterologous (1)
United States (12) · Belgium (4) · Ireland (4) · Israel (3) · Czechia (2) · Germany (2) · Romania (2) · Italy (1)
Aimee Smart (2) · Jayme E Locke, MD (1) · Ronald J Oudiz, MD (1) · Ted Staub, MS, MEng (1)